Trade Alert: The Independent Director Of Corcept Therapeutics Incorporated (NASDAQ:CORT), George Baker, Has Just Spent US$578k Buying A Few More Shares

Trade Alert: The Independent Director Of Corcept Therapeutics Incorporated (NASDAQ:CORT), George Baker, Has Just Spent US$578k Buying A Few More Shares

View photos

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Corcept Therapeutics Incorporated (NASDAQ:CORT) shareholders (or potential shareholders) will be happy to see that the Independent Director, George Baker, recently bought a whopping US$578k worth of stock, at a price of US$12.49. There’s no denying a buy of that magnitude suggests conviction in a brighter future, although we do note that proportionally it only increased their holding by 0.9%.” data-reactid=”28″>Corcept Therapeutics Incorporated (NASDAQ:CORT) shareholders (or potential shareholders) will be happy to see that the Independent Director, George Baker, recently bought a whopping US$578k worth of stock, at a price of US$12.49. There’s no denying a buy of that magnitude suggests conviction in a brighter future, although we do note that proportionally it only increased their holding by 0.9%.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content=" View our latest analysis for Corcept Therapeutics ” data-reactid=”29″> View our latest analysis for Corcept Therapeutics

The Last 12 Months Of Insider Transactions At Corcept Therapeutics

In fact, the recent purchase by George Baker was the biggest purchase of Corcept Therapeutics shares made by an insider individual in the last twelve months, according to our records. We do like to see buying, but this purchase was made at well below the current price of US$19.87. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn’t tell us much about what they think of current prices.

The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

insider-trading-volumeinsider-trading-volume
insider-trading-volume

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.” data-reactid=”49″>There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Insider Ownership of Corcept Therapeutics

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. It’s great to see that Corcept Therapeutics insiders own 9.8% of the company, worth about US$226m. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.

So What Do The Corcept Therapeutics Insider Transactions Indicate?

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="The recent insider purchase is heartening. And the longer term insider transactions also give us confidence. When combined with notable insider ownership, these factors suggest Corcept Therapeutics insiders are well aligned, and quite possibly think the share price is too low. Looks promising! So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Case in point: We've spotted 1 warning sign for Corcept Therapeutics you should be aware of.” data-reactid=”53″>The recent insider purchase is heartening. And the longer term insider transactions also give us confidence. When combined with notable insider ownership, these factors suggest Corcept Therapeutics insiders are well aligned, and quite possibly think the share price is too low. Looks promising! So while it’s helpful to know what insiders are doing in terms of buying or selling, it’s also helpful to know the risks that a particular company is facing. Case in point: We’ve spotted 1 warning sign for Corcept Therapeutics you should be aware of.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Of course Corcept Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.” data-reactid=”54″>Of course Corcept Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.” data-reactid=”55″>For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.” data-reactid=”56″>This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

Leave a Reply

Your email address will not be published. Required fields are marked *